Our study corroborates an early pioneering study by Bob Schreiber and colleagues, which demonstrated that IFNγR1 truncation in methA fibrosarcoma decreased tumor immunogenicity and responsiveness to LPS therapy59. Here, IFNGR1 is linked to fibrosarcoma.